Please login to the form below

Not currently logged in

Vedanta Biosciences appoints two new heads

Lisa Schopf and Erik Spek join the firm
Vedanta Biosciences Erik Spek

Vedanta Biosciences has appointed Lisa Schopf as head of preclinical development and Erik Spek as head of intellectual property.

Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.

Schopf formerly served as the senior director of preclinical development at Kala Pharmaceuticals and has over 20 years of industry experience.

Spek joins from Epizyme, a clinical stage biopharmaceutical company focused on epigenetic targets, where he worked as director of intellectual property.

Bernat Olle, CEO of Vedanta Biosciences, said: “We are delighted to welcome Lisa and Erik to the team. This is an exiting time for Vedanta, and their experience and leadership will be invaluable as we advance our pipeline of drug candidates and scale our discovery platform.”

14th October 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....